Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Clorox Co (CLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Clorox Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Clorox Co trades at $108.39 (market cap $13.09B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.3× Clorox Co's market cap, and Clorox Co pays a 4.62% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CLX | |
|---|---|---|
Market Cap | $29.60B | $13.09B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $127.16 |
52-Week Low | $205.48 | $86.12 |
Enterprise Value | $27.56B | $18.47B |
Dividend Yield | — | 4.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Clorox (CLX) trades at $105.69, down 1.87% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Recent Q4 2026 earnings beat expectations with EPS of $1.66 versus $1.64 estimated, though revenue trends remain pressured by inflation and consumer value-seeking. The company increased its quarterly dividend to $1.25 per share, signaling confidence in cash flow stability.
Outlook is cautious amid margin pressures and competitive threats, with Wall Street largely neutral (69% hold rating). The consensus price target of $97.50 suggests limited upside from current levels, while debt-to-asset ratio rising to 66.4% in 2026 highlights balance sheet risks. Investment appeal hinges on successful cost management and category recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Clorox Co
With a history dating back more than 100 years, Clorox now plays in a variety of categories across the consumer products space, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water-filtration products, and natural personal-care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. Just shy of 85% of Clorox's sales stem from its home turf.
Read more on CLX →
